Data as of Apr 17
| +0.16 / +1.94%|
The 3 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 7.00, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a -16.77% decrease from the last price of 8.41.
The current consensus among 3 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.